Coherent Medical Group

Coherent Biopharma (also known as Tongyuankang Pharmaceutical) is a clinical-stage biotechnology company headquartered in Suzhou, China, specializing in the development of innovative oncology treatments. The company is a pioneer in the Bi-ligand Drug Conjugate (BDC) space, utilizing a proprietary platform that employs two distinct small-molecule ligands to deliver cytotoxic agents specifically to tumor cells. Its lead candidate, CBP-1008, targets both Folate Receptor alpha (FRα) and TRPV6 and is currently undergoing Phase 2 clinical trials for platinum-resistant ovarian cancer and other solid tumors. In addition to its conjugate programs, Coherent Biopharma is developing a robust portfolio of small-molecule kinase inhibitors, including TY-9591, a third-generation EGFR inhibitor for non-small cell lung cancer. By combining targeted conjugates with precision small molecules, the company aims to address unmet medical needs and overcome drug resistance in various cancers.